Supplementary Data from Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

MLA

Bernard M. Fine, et al. Supplementary Data from Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22441422.v1.

APA

Bernard M. Fine, Andrea Pirzkall, Wei Yu, Lukas C. Amler, Benjamin Solomon, David Macfarlane, Barbara J. Gitlitz, Veena Charu, Paul L.R. Mitchell, Brett G.M. Hughes, Rodney J. Hicks, & Linda Mileshkin. (2023). Supplementary Data from Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. https://doi.org/10.1158/1078-0432.22441422.v1

Chicago

Bernard M. Fine, Andrea Pirzkall, Wei Yu, Lukas C. Amler, Benjamin Solomon, David Macfarlane, Barbara J. Gitlitz, et al. 2023. “Supplementary Data from Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib,” March. doi:10.1158/1078-0432.22441422.v1.